arrow
R

Ruth Riisnaes

The Institute of Cancer Research
H指数:41
被引数:9,977

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes

PERSEUS1:一项开放标签、研究者发起的、单臂、II期临床试验,旨在评估帕博利珠单抗在错配修复缺陷型及其他免疫敏感分子亚型的转移性去势抵抗性前列腺癌患者中的疗效。

2025-06-010
OAAI
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
2024-09-170
OAAI
RNASEH2B loss and PARP inhibition in advanced prostate cancer
2024-06-040
OAAI
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2024-02-272
OAAI
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer

一种新的BAG-1L-Specific抗体的开发和验证,以量化晚期前列腺癌中的BAG-1L蛋白表达

2023-11-011
OAAI
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
2023-09-294
OAAI
BCL2 expression is enriched in AR-independent advanced prostate cancer
2023-06-021
PRE
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer (vol 83, pg 224, 2023)

B7-H3作为晚期前列腺癌的治疗靶点 (第83卷,224页,2023页)

2023-06-011
OA
Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787)
2023-04-142
PRE
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer

转移性去势抵抗性前列腺癌的免疫标志物

2022-12-0114
PRE
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2022-10-237
OAAI
A Phase I Trial of CT900, a Novel a-Folate Receptor- Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

新型 α-叶酸受体介导的胸苷酸合成酶抑制剂CT900在具有高级别浆液性卵巢癌患者扩展队列的实体瘤患者中的I期试验

2022-08-194
OAAI
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

guadecitabine (SGI-110) 联合pembrolizumab治疗实体瘤患者的1期剂量递增研究

2022-06-1826
OAAI
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Toparp-b试验中与PARP抑制剂在前列腺癌中获益相关的生物标志物

2021-05-2799
OAAI
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
2021-02-1530
OA
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
2021-02-0186
OAAI
Targeting the p300/CBP Axis in Lethal Prostate Cancer

靶向p300/CBP轴在致死性前列腺癌中的作用

2021-01-11152
OA